HER2 Negative Breast Cancer - SAR439859 - ER mutation

Association details:

Biomarker:	ER mutation
Cancer:	HER2 Negative Breast Cancer
Drug:	amcenestrant (SAR439859) (Selective estrogen receptor degrader)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

SABCS 2020

Title:

A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anticancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1

Published date:

11/17/2020

Excerpt:

Eligible pts were heavily pre-treated, postmenopausal women with ER+/HER2- Mbc...Among heavily pre-treated pts, SAR439859 demonstrated antitumor activity, similar to historical single-agent fulvestrant activity in less heavily pre-treated pts with advanced/mBC (2L+ setting; no prior targeted agents) (indirect comparison). In both subsets of pts with fewer prior advanced lines of therapy, SAR439859 showed trends of greater clinical activity versus historical fulvestrant activity. SAR439859 had a favorable safety profile with limited TRAEs...